No retraction, correction or concern found when last checked on Oct 17, 2026.
The Macrophage Switch in Obesity Development
Angela Castoldi, Cristiane Naffah de Souza, Niels Olsen Saraiva Câmara and 1 more (opens in a new tab)
Frontiers in Immunology · 2016 · Review
doi:10.3389/fimmu.2015.00637 (opens in a new tab)
Abstract
Immune cell infiltration in (white) adipose tissue (AT) during obesity is associated with the development of insulin resistance. In AT, the main population of leukocytes are macrophages. Macrophages can be classified into two major populations: M1, classically activated macrophages, and M2, alternatively activated macrophages, although recent studies have identified a broad range of macrophage subsets. During obesity, AT M1 macrophage numbers increase and correlate with AT inflammation and insulin resistance. Upon activation, pro-inflammatory M1 macrophages induce aerobic glycolysis. By contrast, in lean humans and mice, the number of M2 macrophages predominates. M2 macrophages secrete anti-inflammatory cytokines and utilize oxidative metabolism to maintain AT homeostasis. Here, we review the immunologic and metabolic functions of AT macrophages and their different facets in obesity and the metabolic syndrome.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.
Introduction
Obesity is a prevalent metabolic disease characterized by excess accumulation of white adipose tissue (AT) due to increased food intake and changes in lifestyle. Obesity leads to the development of a low-grade systemic chronic inflammatory state. According to the World Health Organization (WHO), 39% of adults over 18 years of age are overweight and 13% are clinically obese, translating to approximately 2 billion overweight adults where more than half a billion are obese.
A major player in systemic low-grade chronic inflammation in obesity is the increased numbers of AT pro-inflammatory macrophages and deregulated production and function of AT hormones and cytokines. Besides its role in storing energy, AT is an important endocrine organ, such that its dysfunction strongly contributes to the initiation and exacerbation of type 2 diabetes (T2D).
Insulin resistance is defined as a reduced response to insulin in liver, muscle, and AT. This impairment is due to the inhibition of the insulin-signaling pathway, leading to hyperglycemia. Insulin resistance is commonly associated with obesity and may precede the onset of T2D. One hypothesized reason for impaired insulin signaling has been thought to be due to the chronic systemic low-grade inflammation in obesity.
The finding that infiltration of monocytes, which differentiate into macrophages, is augmented in obesity is fundamental. This results in pro-inflammatory macrophage and polarization leading to AT inflammation and insulin resistance. Importantly, macrophages are crucial for regulating the immune system, specifically by restoring and maintaining AT homeostasis.
In this review, we highlight the different functions of AT macrophages (ATMs) in the maintenance AT tissue homeostasis during lean, obese, and insulin resistant states.
Adipose Tissue Macrophages
The mechanisms by which inflammation increases during obesity are not fully understood. Increased pro-inflammatory cytokine secretion contributes to insulin resistance in obesity. Among these cytokines, tumor necrosis factor-α (TNF-α) was the first cytokine identified to be capable of inducing insulin resistance in adipocytes in vitro. In AT, the secretion of TNF-α is primarily derived from macrophages, and the accumulation of these immune cells in obesity contributes to the development of insulin resistance. This supports a key role for inflammation in the regulation of systemic metabolic homeostasis.
Macrophages make up to 40% of all AT cells in obese mice compared to 10% in lean mice. These cells are increased in AT during obesity due to increased amounts of several factors, including free fatty acids (FFAs), cholesterol, and lipopolysaccharide (LPS). Serum levels of LPS are elevated in obesity and, this cell wall component from Gram-negative bacteria, is linked to changes in the gut microbiota (metabolic endotoxemia). LPS binds to and activates toll-like receptor 4 (TLR4) and its downstream signaling pathways in AT resident cells. These activated macrophages secrete cytokines and chemokines, such as monocyte chemoattractant protein-1 (MCP-1), and express C–C motif chemokine receptor-2 (CCR2) and CCR5, which in turn augment the recruitment of more monocytes and other leukocytes into AT. Macrophages share the same differentiation and recruitment molecules with other myeloid cells in many inflammatory conditions. As observed during bacterial inflammation, in obesity, macrophage activation is dependent on I kappa B kinase-β (IKK-β). Arkan et al. showed that IKK-β activation in macrophages is sufficient for the development of insulin resistance, and mice with loss of IKK-β function only in myeloid cells are protected from obesity development and insulin resistance. These findings demonstrate the importance of macrophages in the context of insulin resistance development.
In addition to the activation and inflammatory profile of macrophages in the obese state, ATMs are highly adaptive to its lipid-rich environment. To maintain AT homeostasis in this lipid-rich microenvironment, macrophages increase their adiposity by activating lysosomal lipid metabolism. This may be a physiological response to buffer the increase in lipid concentrations released by adipocytes during obesity. This process does not classically activate ATMs, but it activates an immune cell differentiation program where high concentrations of lipids and FFAs induce a macrophage phenotype distinct from differentiated bone marrow macrophages (BMDM). This phenotype is characterized by lipid accumulation in ATMs and increased expression of fatty acids transporters, such as CD36 and the lipid scavenger receptor Msr1.
Several immune cells regulate AT inflammation, insulin resistance, and macrophage recruitment and differentiation. There are two distinct macrophage populations found in AT. In healthy/lean AT, alternatively activated macrophages (M2) that express CD206 and CD301 on their surface and secrete anti-inflammatory cytokines predominates. On the other hand, obesity triggers the accumulation of classically activated macrophages (M1) characterized by CD11c surface expression, and expression of pro-inflammatory cytokines, although this pan-classification spans a broad range of macrophage subtypes.
However, Kratz et al. recently described a different subtype of macrophage. They observed that treating macrophages with a mix of glucose, palmitate, and insulin (“metabolic activation”) generates a unique macrophage pro-inflammatory phenotype that is different from M1. This type of macrophage secretes pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and TNF-α, whereby the secretion is dependent on peroxisome proliferator-activated receptor gamma (PPAR-γ) and p62 expression. In vivo, this phenotype is due to continuous and excessive exposure of ATMs to FFAs, such as palmitate, in a microenvironment that is saturated with glucose and insulin. In obesity, this differentiated macrophage subtype indicates the importance and the necessity to identify differentiated profiles of immune cells. Since there is a large spectrum of ATMs that have different immune profiles, we choose to focus on M1 and M2 subtypes of ATMs to better understand how metabolic alterations in ATMs impact obesity and insulin resistance.
M1 Macrophages: An Overview
M1 macrophages are associated with a pro-inflammatory profile. These macrophages are generally stimulated by T-helper 1 (Th1) type of cytokines, such as interferon-γ (IFN-γ), or by pathogen-associated molecular patterns (PAMPs), such as LPS. In turn, M1 macrophages secrete cytokines, including IL-6, TNF-α, IL-1β, IL-12, and IL-23. M1 macrophages can also induce Th1 responses. In general, these cells express high levels of major histocompatibility complex class II (MHC-II), CD80 and CD86 costimulatory molecules and CD68. Moreover, M1 macrophages express Th1 cell-attracting chemokines, including CXCL9 and CXCL10.
In addition to IFN-γ and LPS, there are several other molecules involved in M1 macrophage polarization, such as interferon regulatory factor (IRF), signal transducers and activators of transcription (STAT), and suppressor of cytokine signaling (SOCS). IRF5 is involved in M1 polarization by inducing the transcription of interleukin-12 subunit p40 (IL-12p40), IL-12p35, and IL-23p19, and by repressing the transcription of IL-10. M1 macrophages express SOCS3, which promotes nitric oxide (NO) production. SOCS3 controls nuclear factor-κB (NF-κB) and phosphatidylinositol 3-kinase (PI3K) activity, favoring NO production in macrophages. The induction of inducible nitric oxide synthase (iNOS), another important molecule induced in M1 macrophages is dependent on TLR ligands, such as LPS, and activation of NF-κB, PI3K, and IFN-γ secretion (Table 1). Furthermore, myeloid differentiation primary response gene 88 (MyD88)-dependent pathway is also important for M1 polarization. The expression of TLR4/TLR2 is significantly higher in M1 when compared to M2 macrophages. The absence of TLR4 drives macrophages toward an M2 phenotype, indicating that activation and polarization of macrophages is, at least, in part dependent on TLRs.
In contrast to M1 macrophages generated in vitro, which do not express CD11c, M1 ATMs express CD11c concomitant with F4/80 and CD11b. Interestingly, the expression of CD11c in vitro by BMDM can be induced if BMDMs are differentiated in the presence of adipocytes. This indicates the importance and requirement of adipocytes in orchestrating the functional phenotype of ATMs.
The recruitment of monocytes, which in AT gives rise to CD11c+ ATMs, is dependent on CCR2, CCR5, and MCP-1. Nagareddy et al. demonstrated that ATM-derived IL-1β promotes monocyte release from the bone marrow and MCP-1 induces M1 ATM proliferation in AT. These processes are important to promote macrophage accumulation in the AT during obesity and sustain AT inflammation and insulin resistance.
Polarizing M1 ATMs: How They Induce Insulin Resistance
Obesity-associated insulin resistance correlates with elevated levels of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6. These cytokines are secreted by both adipocytes and ATMs due to increased levels of pro-inflammatory factors released during obesity development. These factors include FFA, triglycerides, resistin, leptin, retinol-binding protein 4 (RBP4), IL-6, TNF-α, and IL-1β, among others.
Secretion of these factors activates several inflammatory signal transduction pathways in macrophages and adipocytes, which are required for obesity-induced insulin resistance. The stress-responsive c-Jun NH2-terminal kinase (JNK 1 and 2), inhibitor of κB kinase (IKK), extracellular signal-regulated kinase 1 and 2 (ERK 1 and 2), and mitogen-activated protein kinase p38 (p38 MAPK) are responsible for alterations in the insulin receptor signaling pathway. These alterations lead to decreased tyrosine phosphorylation of insulin receptor substrate (IRS-1 and -2), PI3K activation followed by a decreased serine phosphorylation of Akt and consequently insulin resistance. There is a crosstalk between the two isoforms of JNK (JNK1 and JNK2) that contributes to obesity-induced insulin resistance development. The balance between these two molecules determines the total activity of JNK in fat tissues. Hematopoietic activation of JNK1 is a major player in obesity-induced inflammation and insulin resistance. Corroborating this, Han et al. verified that knockdown of both JNK 1 and 2 in macrophages protect mice from HFD-induced insulin resistance and AT inflammation. Similarly, Vallerie et al. showed that myeloid JNK1 is a regulator of cytokine expression in AT during the late, but not early states of obesity development.
Toll-like receptors and inflammasomes are activated in obesity by damage-associated molecular pattern molecules (DAMPs), such as high-mobility group box 1 (HMGB1) and oxidized low-density lipoprotein (Ox-LDL), RBP4 or PAMPs, such as LPS. TLRs and inflammasomes modulate macrophage polarization due to activation of NF-κB, STAT1, and caspase-1 to induce IL-1β production. Upon activation, these receptors contribute to low-grade chronic inflammation in obesity, leading to M1 polarization of ATMs. Importantly, TLR4 expression is increased in ATMs during obesity. Thus, many studies have investigated the role of TLR4 and nod-like receptor protein 3 (NLRP3) in knockout mouse models in HFD-induced obesity.
Toll-like receptor 4 deficiency in HFD-fed mice ameliorates AT inflammation, insulin resistance, and adiposity. The reduction in inflammation is due to decreased macrophage infiltration and a switch from M1 to M2 macrophage profile.
Nod-like receptor protein 3 inflammasome also plays a key role in the development of AT inflammation and insulin resistance. Expression of NLRP3, apoptosis-associated speck-like protein containing CARD (ASC), caspase-1, and IL-1β are all upregulated in AT of obese mice, as well as the mature form of IL-1β. The secreted IL-1β binds to IL-1R and activates NF-κB and MAPK pathways, thereby impairing insulin signaling through the activation of IRS-1 in adipocytes leading to insulin resistance.
Functional deletion of NLRP3 and caspase-1 ameliorate HFD-induced insulin resistance and AT inflammation. Moreover, weight loss and insulin sensitivity in patients with T2D is associated with decreased AT expression of NLRP3 and IL-1β. Protection from insulin resistance and inflammation following loss of functional NLRP3 may be due to a shift in macrophage polarization, since NLRP3-knockout mice have decreased M1 and increased M2 gene expression profiles in AT.
In addition to these important signaling pathways, the mammalian target of rapamycin (TOR) has an important function in insulin resistance. It is able to sense nutrients and respond by altering the cellular metabolism in different kind of cells, including ATMs. Insulin, glucose, leptin, and other growth factors and cytokines activate mTOR pathway via PI3K–Akt signaling pathway. The protein kinase Akt phosphorylates and inhibits TSC2 and, consequently, activates mTORC1. Activation of these metabolic sensors, mainly PI3Kγ, is important for immune cell functions. PI3Kγ activation in hematopoietic cells contributes to the development of obesity and insulin resistance. PI3Kγ activity in the non-hematopoietic compartment is critical during obesity. Moreover, the catalytic subunit of PI3Kγ, p110γ, was shown to be activated during obesity. Absence of functional p110 improved insulin sensitivity with reduced infiltration of pro-inflammatory macrophages and inflammatory marker expression in AT. In addition, specific depletion of PI3Kγ in bone marrow cells as well as pharmacological blockade also inhibited macrophage infiltration during obesity and insulin resistance. Together, these data indicate that activation of metabolic sensors in immune cells during obesity is essential for inflammation and insulin resistance development.
Defects in mTORC1 regulation can lead to metabolic dysfunction, including T2D. Deletion of mTORC1 in macrophages diminishes AT inflammation and protects mice against HFD-induced insulin resistance. mTORC1 disruption suppresses HK1-dependent glycolysis, caspase-1 activation, IL-1β, and IL-18 secretion in vitro and in vivo and induces M2 polarization. In accordance, Jiang et al. showed that mTORC1 depletion in macrophages protects mice against HFD-induced AT inflammation and insulin resistance through the inhibition of IRE1α/JNK/NF-κB pathways.
In 2013, Horng et al. demonstrated in vitro and in vivo that TSC1 deletion (Tsc1 deficiency, thereby mTORC1 is constitutively active) in macrophages leads to a marked defect in M2 polarization in response to IL-4, although LPS stimulation induced inflammatory responses in an mTOR-dependent manner. Moreover, in obesity, nutrient sensing by mTORC1 regulates the switch of ATMs from M2 to M1.
More recently, Zhu et al. proposed that TSC1 deletion in macrophages intensifies the M1 polarization. TSC1 inhibits M1 polarization by suppressing the Ras GTPase/Raf1/MEK/ERK signaling pathway in an mTOR-independent manner, whereas TSC1 promotes M2 properties by mTOR-dependent CCAAT/enhancer-binding protein-β pathway. These findings indicate a critical role for TSC1 in orchestrating macrophage polarization via mTOR-dependent and -independent pathways (Figure 1).
Increased M1 activation in AT is involved in activation of the adaptive immune response through the recruitment and activation of T cells. Increased recruitment of CD4+ T cells correlates with increased M1 polarization. Also, M1 polarization appears to be dependent on AT Th1 polarization. In addition, during obesity, the activation of Th1 responses in AT are mediated by mTORC1, since this molecule is necessary for polarization of T lymphocytes toward a Th1 phenotype. Moreover, circulating leptin, which is elevated during obesity, activates mTOR pathway, and also induces Th1 responses. Thus, Th1 polarization is dependent on M1 polarization, and it is critical for the development of insulin resistance.
Together, several pathways mediate the induction/activation of ATMs to maintain AT homeostasis, which can also be affected by changes in systemic and cellular metabolism.
M2 Macrophage: An Overview
M2 macrophages are associated with tissue remodeling and inflammation resolution. M2 macrophages have immunosuppressive properties, have high phagocytic capacity, and secrete extracellular matrix components, angiogenic and chemotactic factors, anti-inflammatory cytokines, and growth factors, such as IL-10 and transforming growth factor β (TGF-β). M2 macrophages are characterized by upregulated expression of Dectin-1, CD206, scavenger receptor A, scavenger receptor B-1, CD163, CCR2, CXCR1, CXCR2, and MgL 1/2. Moreover, the expression of arginase-1 (Arg1), PPAR-γ, and transcription factor found in inflammatory zone 1 (FIZZ1), which is specific of murine M2 macrophages, are necessary for collagen synthesis, further supporting the role of these cells in tissue remodeling (Table 1).
In vitro, M2 macrophages appear to be a heterogeneous population induced by a variety of stimuli. M2a is induced by IL-4 or IL-13 express high levels of CD206 and has immunoregulatory functions. M2b is induced by immune complexes and TLRs or IL-1R agonists. Both M2a and M2b have an immunoregulatory role through down-regulation of IL-12, IL-6, and TNF. M2c is induced by IL-10 and glucocorticoids. It has an immunosuppressive phenotype and participates in tissue remodeling. M2c secretes pro-fibrotic factors, such as TGF-β, CCL17, and CCL22. In addition, expansion of M2c macrophages is negatively regulated by PPAR-γ, which is expressed in M2 ATM. Although significant progress has been made in characterizing M2 subpopulations, it still not completely understood how these cells behave in vivo.
M2 ATMs and Insulin Sensitivity
The microenvironment in a lean AT is composed of a 4:1 M2:M1 ratio. The presence of eosinophils and regulatory T cells (Tregs), which secrete the cytokines IL-4/IL-13 and IL-10, respectively, polarizes ATMs toward an anti-inflammatory phenotype. In lean AT, adipocytes secrete higher levels adiponectin compared with obese AT. Adiponectin enhances insulin sensitivity and increases M2 macrophage polarization. These cells and their secretome maintain the positive balance of M2 macrophages in lean AT.
Obesity inversely correlates with AT Tregs. Moreover, Tregs can induce M2 macrophage differentiation in mice through IL-10 and TGF-β. In lean AT, these cells are involved in the regulation of tissue homeostasis and help to maintain the M2 macrophage population.
Recently, new regulatory players in AT homeostasis have been identified: innate lymphoid type 2 cells (ILC2s) and IL-33. ILC2s are a regulatory subtype of ILCs. These cells were divided into three distinct populations, ILCs 1, 2, and 3. These subpopulations of ILCs are analogous to the largely known CD4+ T helper subsets: Th1, Th2, and Th17, respectively, with respect to cytokine profile expression. However, ILCs do not have T-cell receptors and respond to antigenic signals in the absence of antigen specificity. ILCs are activated by the cytokine IL-33 and produce large amounts of the type 2 cytokines: IL-5 and IL-13.
Interleukin-33 is constitutively present in humans and mice, mainly in specialized populations of epithelial and endothelial cells. Its receptor (ST2) is highly expressed in ILC2s and Th2 lymphocytes, and it is also found in eosinophils, mast cells, dendritic cells, basophils, myeloid-derived suppressor cells, and Tregs.
Interleukin-33, as well as ILC2s, has been in the spotlight due to their putative contributions in the improvement of obesity-induced insulin resistance. Upon binding to its receptor, IL-33 induces the production of large amounts of anti-inflammatory cytokines by AT ILC2s and also the polarization of ATMs toward an M2 phenotype. This results in AT mass reduction and improves insulin resistance. Han and colleagues investigated ST2 expression in murine Tregs in lean and obese visceral AT. AT Tregs from lean mice express higher levels of ST2 compared to AT Tregs from obese mice. Moreover, treatment with IL-33 restored the ST2-positive Treg population, reduced AT inflammation, and improved insulin resistance.
In this context, Brestoff et al. demonstrated that IL-33 plays an important role in the maintenance of ILC2s in AT, promoting energy expenditure, and reducing adiposity in mice. This decrease in adiposity was due to caloric expenditure upon the induction of uncoupling protein 1 (UCP1) expression in AT, a process called “beiging” or “browning”. UCP1 protein is limited to beige and brown adipocytes and regulates caloric expenditure. In agreement with Artis et al., Chalwa’s et al. found that IL-33 promoted the accumulation and activation of ILC2s in mouse AT, leading to the biogenesis of beige fat, which is crucial for AT metabolic homeostasis (Figure 1).
Taken together, these studies demonstrate the importance of alternatively activated macrophages to maintain the tissue homeostasis, especially in AT. Moreover, the discovery of new alternative pathways for the polarization of ATMs toward an M2 phenotype is necessary to better understand the mechanisms by which insulin sensitivity in obesity.
Macrophage Metabolism and Its Role in Insulin Sensitivity
In addition to cytokines, the availability of substrates in tissues orchestrates macrophage function. Cellular metabolism is not static but is rather a dynamic process that allows cells to adapt to the microenvironment. The type of nutrient substrate is critical for ATM function. Saturated fatty acids (SFAs) are pro-inflammatory and induce M1-like phenotype, while certain types of unsaturated fatty acids (UFAs), such as omega-3 and branched fatty acid esters of hydroxy fatty acids (FAHFA), are anti-inflammatory and induce an M2-like phenotype.
M1 macrophages preferentially metabolize glucose as an energy substrate. During activation, macrophages alter its metabolism to support survival and cellular functions. The metabolism of M1 macrophages upon activation is characterized by induced aerobic glycolysis with increased glucose uptake and the conversion of pyruvate to lactate by lactate dehydrogenase (LDH). This activation in aerobic glycolysis decreases respiratory chain activity due to increased ROS levels. This metabolic switch is necessary for NO production, an important effector of immune microbicidal activity and pro-inflammatory M1 macrophage responses.
In addition, the expression of glucose transporter-1 (GLUT-1) drives the pro-inflammatory phenotype of M1 macrophages, increases glucose uptake, and, subsequently, augments glucose metabolism.
One important molecule regulating glycolysis and macrophage activation is hypoxia inducible factor-1α (Hif-1α). Hif-1α induces a pro-inflammatory phenotype in macrophages via TLR4 activation, which involves the PI3K/Akt signaling pathway. Low oxygen (O2) tension and inflammatory responses increase TLR4 expression in macrophages. Moreover, M1 macrophages co-localize with AT hypoxic areas in obese mice and are associated with increased inflammatory responses. Because these macrophages need to adapt to the obesity-induced hypoxic tissue environment, activating anaerobic glycolysis under these circumstances best serves these immune cells to support their rapid and demanding energy requirements.
Activation of macrophages with LPS also results in increased levels of succinate and malate. Succinate, in particular, drives IL-1β production, which is dependent on Hif-1α activation. In addition, pyruvate kinase M2 (PKM2), a critical determinant of macrophage activation by LPS, promotes inflammatory responses. Activation of PKM2 plays a key role in stabilizing Hif-1α and Hif-1α-dependent genes, such as IL-1β expression. LPS induces dimerization of PKM2 that in turn complexes with Hif-1α. This complex directly binds to the IL-1β promoter, an event that is inhibited by the activation of tetrameric PKM2, which induces M2 macrophage differentiation and attenuates LPS-induced M1 macrophages. Thus, PKM2 in its dimeric form is required for glycolytic reprograming in response to LPS. The dimeric form of PKM2 plays role in Hif-1α function, whereas the tetrameric form of PKM2 impairs the ability of PKM2 to promote transcriptional activity of Hif-1α and LPS-induced IL-1β expression.
Nonetheless, the microenvironment rich in LPS and IFN-γ also enhances M1 macrophage polarization and glycolysis activation independently of Hif-1α. This occurs upon 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2) induction.
In contrast to M1 glycolytic metabolism, M2 macrophages utilize oxidative metabolism. The induction of oxidative metabolism in M1 macrophages shifts their phenotype toward an M2 profile. Moreover, the overexpression of carbohydrate kinase-like protein (CARKL), which regulates the production of sedoheptulose-7-phosphate (S7P), an intermediate of the pentose phosphate pathway (PPP) results in decreased production of pro-inflammatory cytokines, which suggests a shift toward an M2 macrophages phenotype.
Besides CARKL, the coactivator protein PPAR-γ-coactivator-1β (PGC1-β) induces mitochondrial respiration as well as mitochondrial biogenesis. This is a key player in the metabolic switch of macrophages from M1 to M2 phenotype. Blocking PGC1-β results in impaired M2 macrophage metabolism and function. Thus, identifying mechanisms that modulate the metabolism of macrophages may dampen the onset and exacerbation of inflammatory processes.
Adipose tissue-derived IL-4 and IL-13 signals through IRF/STAT to activate STAT6 in M2 macrophages. STAT6 induces the expression of transcriptional regulators, such as PPAR-γ. PPAR-γ maintains the metabolic switch toward oxidative metabolism and promotes M2 gene expression (Arg1) to amplify the effector phenotype of M2 macrophages (collagen synthesis). Other members of the PPAR family, PPARβ/δ, appears to differentially influence macrophage activation, along with IL-4 and IL-13, and promotes an alternative M2 macrophage phenotype. Myeloid deletion of PPARβ/δ leads to glucose intolerance and insulin resistance, indicating that expression of PPARs transcription factors is crucial to maintain the M2 phenotype through the secretion of Th2 cytokines (Figure 1).
Hypoxia inducible factor-2α has been shown to regulate the transcription of Arg1, which is expressed by M2 macrophages. However, Hif-2α also controls IL-1β production and NF-κB activity, which is associated with an M1 phenotype. Thus, although Hif-2α appears to have a role in macrophage polarization, more studies are needed to better understand the importance of this transcription factor for macrophage phenotype, metabolism, and function.
It is still unclear how M2 macrophages metabolism is regulated during obesity and the role of M2 macrophage metabolism for the development of insulin resistance. Nevertheless, in lean state, they have an oxidative metabolism, which may shift to glycolytic metabolism, during obesity, due to a pro-inflammatory environment and further studies are needed to better understand their role in obesity.
Conclusion
Macrophages are central mediators of obesity-induced AT inflammation and insulin resistance. They also are key cells for maintenance of AT homeostasis. Recently, several reports described the importance of these cells as regulators of insulin sensitivity, which involves the activation of innate immune receptors, transcription factors, and intracellular metabolism to support the either pro- or anti-inflammatory AT phenotype. Thus, macrophages have a dual role, changing their status to support immune responses, obesity development, and related diseases.
Author Contributions
AC and CN have contributed equally in the writing of this manuscript. NC and PM-V contributed in the writing and corrections of this manuscript. AC and CN have contributed equally to this review.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References 157
- 1.
Kopelman PG. Obesity as a medical problem. Nature (2000 ) 404:635–43.
Not in our library10.1038/35007508 (opens in a new tab)
- 2.
Mokdad AH Ford ES Bowman BA Dietz WH Vinicor F Bales VS Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA (2003 ) 289:76–9.
Not in our library10.1001/jama.289.1.76 (opens in a new tab)
- 3.
Hotamisligil GS Shargill NS Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993 ) 259:87–91.
Not in our library10.1126/science.7678183 (opens in a new tab)
- 4.
Xu H Barnes GT Yang Q Tan G Yang D Chou CJ Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003 ) 112:1821–30.
Not in our library10.1172/jci200319451 (opens in a new tab)
- 5.
Qatanani M Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev (2007 ) 21:1443–55.
Not in our library10.1101/gad.1550907 (opens in a new tab)
- 6.
Hotamisligil GS Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol (2008 ) 8:923–34.
Not in our library10.1038/nri2449 (opens in a new tab)
- 7.
WHO. World Health Organization. Obesity and Overweight, 2015 [Online] (2015 ). Available from: http://www.who.int/mediacentre/factsheets/fs311/en/
Not in our library
- 8.
Kershaw EE Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab (2004 ) 89(6):2548–56.
Not in our library10.1210/jc.2004-0395 (opens in a new tab)
- 9.
Andrade-Oliveira V Camara NO Moraes-Vieira PM Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res (2015 ) 2015:681612
Not in our library10.1155/2015/681612 (opens in a new tab)
- 10.
Moraes-Vieira PM Bassi EJ Araujo RC Camara NO. Leptin as a link between the immune system and kidney-related diseases: leading actor or just a coadjuvant? Obes Rev (2012 ) 13:733–43.
Not in our library10.1111/j.1467-789x.2012.00997.x (opens in a new tab)
- 11.
Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) (2001 ) 226:13–26.
Not in our library10.1177/153537020122600103 (opens in a new tab)
- 12.
Chawla A Nguyen KD Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol (2011 ) 11:738–49.
Not in our library10.1038/nri3071 (opens in a new tab)
- 13.
Lee BC Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta (2014 ) 1842:446–62.
Not in our library10.1016/j.bbadis.2013.05.017 (opens in a new tab)
- 14.
Laakso M Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol (2014 ) 10:293–302.
Not in our library10.1038/nrendo.2014.29 (opens in a new tab)
- 15.
Kanda H Tateya S Tamori Y Kotani K Hiasa K Kitazawa R MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest (2006 ) 116:1494–505.
Not in our library10.1172/jci26498 (opens in a new tab)
- 16.
Masoodi M Kuda O Rossmeisl M Flachs P Kopecky J Lipid signaling in adipose tissue: connecting inflammation & metabolism. Biochim Biophys Acta (2015 ) 1851:503–18.
Not in our library10.1016/j.bbalip.2014.09.023 (opens in a new tab)
- 17.
Lumeng CN Bodzin JL Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest (2007 ) 117:175–84.
Not in our library10.1172/jci29881 (opens in a new tab)
- 18.
Ferrante AW Jr. Macrophages, fat, and the emergence of immunometabolism. J Clin Invest (2013 ) 123:4992–3.
Not in our library10.1172/jci73658 (opens in a new tab)
- 19.
Brestoff JR Artis D. Immune regulation of metabolic homeostasis in health and disease. Cell (2015 ) 161:146–60.
Not in our library10.1016/j.cell.2015.02.022 (opens in a new tab)
- 20.
Hofmann C Lorenz K Braithwaite SS Colca JR Palazuk BJ Hotamisligil GS Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology (1994 ) 134:264–70.
Not in our library10.1210/en.134.1.264 (opens in a new tab)
- 21.
Hotamisligil GS Budavari A Murray D Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest (1994 ) 94:1543–9.
Not in our library10.1172/jci117495 (opens in a new tab)
- 22.
Hotamisligil GS Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes (1994 ) 43:1271–8.
Not in our library10.2337/diab.43.11.1271 (opens in a new tab)
- 23.
Weisberg SP McCann D Desai M Rosenbaum M Leibel RL Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003 ) 112:1796–808.
Not in our library10.1172/jci200319246 (opens in a new tab)
- 24.
- 25.
Wang P Mariman E Renes J Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol (2008 ) 216:3–13.
Not in our library10.1002/jcp.21386 (opens in a new tab)
- 26.
Kosteli A Sugaru E Haemmerle G Martin JF Lei J Zechner R Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest (2010 ) 120:3466–79.
Not in our library10.1172/jci42845 (opens in a new tab)
- 27.
Olefsky JM Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol (2010 ) 72:219–46.
Not in our library10.1146/annurev-physiol-021909-135846 (opens in a new tab)
- 28.
Pollard JW Trophic macrophages in development and disease. Nat Rev Immunol (2009 ) 9:259–70.
Not in our library10.1038/nri2528 (opens in a new tab)
- 29.
Yang F Tang E Guan K Wang CY. IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol (2003 ) 170:5630–5.
Not in our library10.4049/jimmunol.170.11.5630 (opens in a new tab)
- 30.
Arkan MC Hevener AL Greten FR Maeda S Li ZW Long JM IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005 ) 11:191–8.
Not in our library10.1038/nm1185 (opens in a new tab)
- 31.
Xu X Grijalva A Skowronski A Van Eijk M Serlie MJ Ferrante AW Jr. Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab (2013 ) 18:816–30.
Not in our library10.1016/j.cmet.2013.11.001 (opens in a new tab)
- 32.
Odegaard JI Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science (2013 ) 339:172–7.
Not in our library10.1126/science.1230721 (opens in a new tab)
- 33.
Molofsky AB Nussbaum JC Liang HE Van Dyken SJ Cheng LE Mohapatra A Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med (2013 ) 210:535–49.
Not in our library10.1084/jem.20121964 (opens in a new tab)
- 34.
Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab (2013 ) 17:851–9.
Not in our library10.1016/j.cmet.2013.05.008 (opens in a new tab)
- 35.
Kolodin D Van Panhuys N Li C Magnuson AM Cipolletta D Miller CM Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab (2015 ) 21:543–57.
Not in our library10.1016/j.cmet.2015.03.005 (opens in a new tab)
- 36.
Martinez FO Helming L Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol (2009 ) 27:451–83.
Not in our library10.1146/annurev.immunol.021908.132532 (opens in a new tab)
- 37.
Kratz M Coats BR Hisert KB Hagman D Mutskov V Peris E Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab (2014 ) 20:614–25.
Not in our library10.1016/j.cmet.2014.08.010 (opens in a new tab)
- 38.
Mantovani A Sica A Sozzani S Allavena P Vecchi A Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004 ) 25:677–86.
Not in our library10.1016/j.it.2004.09.015 (opens in a new tab)
- 39.
Goerdt S Politz O Schledzewski K Birk R Gratchev A Guillot P Alternative versus classical activation of macrophages. Pathobiology (1999 ) 67:222–6.
Not in our library10.1159/000028096 (opens in a new tab)
- 40.
Cited by papers we hold 20
- Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets · 2025No notice
- Macrophages: shapes and functions · 2022No notice
- Macrophage-Mediated Inflammation in Skin Wound Healing · 2022No notice
- Adipokines, Hepatokines and Myokines: Focus on Their Role and Molecular Mechanisms in Adipose Tissue Inflammation · 2022No notice
- Inflammation in Metabolic Cardiomyopathy · 2021Not checked
- Macrophage Polarity and Disease Control · 2021No notice
- Meta-Inflammation and Metabolic Reprogramming of Macrophages in Diabetes and Obesity: The Importance of Metabolites · 2021No notice
- Chronic Low Grade Inflammation in Pathogenesis of PCOS · 2021No notice
- Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes · 2020No notice
- Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes · 2020No notice
- Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences · 2020No notice
- Macrophage Polarization and Osteoporosis: A Review · 2020No notice
- The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity · 2019No notice
- Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications · 2019No notice
- Interleukin-18 in Health and Disease · 2019No notice
- Emerging Functions of Regulatory T Cells in Tissue Homeostasis · 2018No notice
- Inflammation – Cause or Consequence of Heart Failure or Both? · 2017No notice
- Macrophage Phenotypes Regulate Scar Formation and Chronic Wound Healing · 2017No notice
- The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications · 2017No notice
- Impact of Mediterranean diet on metabolic syndrome, cancer and longevity · 2016No notice
Questions about this paper
We email you if it is retracted, withdrawn, corrected or flagged.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.